LitAlert ~~ GeneLit.com

    • A Genome-First Approach to Estimate Prevalence of Germline Pathogenic Variants and Risk of Pancreatic Cancer in Select Cancer Susceptibility Genes.
    • Astiazaran-Symonds E, Kim J, Haley JS, Kim SY, Rao HS, Regeneron Genetics Center, Carey DJ, Stewart DR, Goldstein AM.
    • Cancers (Basel). 2022 Jul 2;14(13):3257. doi: 10.3390/cancers14133257.
    • Characteristics of breast cancer patients tested for germline BRCA1/2 mutations by next-generation sequencing in Ramathibodi Hospital, Mahidol University.
    • Oranratnachai S, Yamkaew W, Tunteeratum A, Sukarayothin T, Iemwimangsa N, Panvichien R.
    • Cancer Rep (Hoboken). 2022 Jul 1:e1664. doi: 10.1002/cnr2.1664. Epub ahead of print.
    • Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?
    • Keane F, Park W, O'Reilly EM.
    • JCO Precis Oncol. 2022 Jun;6:e2200141. doi: 10.1200/PO.22.00141.

    Letter, Reply:

    Reply to F. Keane et al.

    Original research:

    Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.